keyword
MENU ▼
Read by QxMD icon Read
search

Gynecologic oncology group

keyword
https://www.readbyqxmd.com/read/28094040/a-phase-2-study-of-alisertib-mln8237-in-recurrent-or-persistent-uterine-leiomyosarcoma-an-nrg-oncology-gynecologic-oncology-group-study-0231d
#1
David M Hyman, Michael W Sill, Heather A Lankes, Richard Piekarz, Mark S Shahin, Mildred R Ridgway, Floor Backes, Meaghen E Tenney, Cara A Mathews, James S Hoffman, Carol Aghajanian, Martee L Hensley
OBJECTIVE: This two-stage Phase II study assessed the activity of single agent alisertib in patients with recurrent/persistent uterine leiomyosarcoma (uLMS). METHODS: Eligibility criteria included histologically-confirmed, recurrent or persistent uLMS, age≥18, 1-2 prior cytotoxic regimens, and RECIST version 1.1 measurable disease. The primary objective of the study was to evaluate the efficacy of alisertib through the frequency of patients with objective tumor responses and the frequency who survived event-free for at least 6months (EFS6)...
January 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28089376/chemotherapy-completion-in-elderly-women-with-ovarian-primary-peritoneal-or-fallopian-tube-cancer-an-nrg-oncology-gynecologic-oncology-group-study
#2
Vivian E von Gruenigen, Helen Q Huang, Jan H Beumer, Heather A Lankes, William Tew, Thomas Herzog, Arti Hurria, Robert S Mannel, Tina Rizack, Lisa M Landrum, Peter G Rose, Ritu Salani, William H Bradley, Thomas J Rutherford, Robert V Higgins, Angeles Alvarez Secord, Gini Fleming
PURPOSE: A simple measure to predict chemotherapy tolerance in elderly patients would be useful. We prospectively tested the association of baseline Instrumental Activities of Daily Living (IADL) score with ability to complete 4 cycles of first line chemotherapy without dose reductions or >7days delay in elderly ovarian cancer patients. PATIENTS AND METHODS: Patients' age ≥70 along with their physicians chose between two regimens: CP (Carboplatin AUC 5, Paclitaxel 135mg/m(2)) or C (Carboplatin AUC 5), both given every 3weeks either after primary surgery or as neoadjuvant chemotherapy (NACT) with IADL and quality of life assessments performed at baseline, pre-cycle 3, and post-cycle 4...
January 12, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28079776/enhanced-recovery-program-and-length-of-stay-after-laparotomy-on-a-gynecologic-oncology-service-a-randomized-controlled-trial
#3
Elizabeth L Dickson, Erica Stockwell, Melissa A Geller, Rachel Isaksson Vogel, Sally A Mullany, Rahel Ghebre, Boris J N Witherhoff, Levi S Downs, Linda F Carson, Deanna Teoh, Michelle Glasgow, Matt Gerber, Colleen Rivard, Britt K Erickson, Jacob Hutchins, Peter A Argenta
OBJECTIVE: To estimate whether a rapid recovery program would reduce length of stay among patients undergoing laparotomy on a gynecologic oncology service. METHODS: We conducted a prospective, randomized, controlled trial comparing an enhanced recovery after surgery protocol with routine postoperative care among women undergoing laparotomy on the gynecologic oncology service. Protocol elements included: preoperative counseling, regional anesthesia, intraoperative fluid restriction, and early postoperative ambulation and feeding...
January 9, 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28068938/acupuncture-combined-with-methylcobalamin-for-the-treatment-of-chemotherapy-induced-peripheral-neuropathy-in-patients-with-multiple-myeloma
#4
Xiaoyan Han, Lijuan Wang, Hongfei Shi, Gaofeng Zheng, Jingsong He, Wenjun Wu, Jimin Shi, Guoqing Wei, Weiyan Zheng, Jie Sun, He Huang, Zhen Cai
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) seriously affects the quality of life of patients with multiple myeloma (MM) as well as the response rate to chemotherapy. Acupuncture has a potential role in the treatment of CIPN, but at present there have been no randomized clinical research studies to analyze the effectiveness of acupuncture for the treatment of CIPN, particularly in MM patients. METHODS: The MM patients (104 individuals) who met the inclusion criteria were randomly assigned into a solely methylcobalamin therapy group (500 μg intramuscular methylcobalamin injections every other day for 20 days; ten injections) followed by 2 months of 500 μg oral methylcobalamin administration, three times per day) and an acupuncture combined with methylcobalamin (Met + Acu) group (methylcobalamin used the same way as above accompanied by three cycles of acupuncture)...
January 9, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28067948/preoperative-assessment-of-lymph-node-metastasis-in-endometrial-cancer-a-korean-gynecologic-oncology-group-study
#5
Sokbom Kang, Joo-Hyun Nam, Duk-Soo Bae, Jae-Weon Kim, Moon-Hong Kim, Xiaojun Chen, Jae-Hong No, Jong-Min Lee, Jae-Hoon Kim, Hidemich Watari, Seok Mo Kim, Sung Hoon Kim, Seok Ju Seong, Ki Tae Kim, Seung Cheol Kim, Jong-Hyeok Kim, Myung-Cheol Lim, Jung-Yun Lee, Sang-Young Ryu, Bingyi Yang, Byoung-Gie Kim
BACKGROUND: Previously proposed criteria for preoperatively identifying endometrial cancer patients at low risk for lymph node metastasis remain to be verified. For this purpose, a prospective, multicenter observational study was performed. METHODS: Eligible patients with histologically confirmed endometrial cancer underwent magnetic resonance imaging (MRI) and serum cancer antigen 125 (CA 125) testing before surgery. The following criteria were used to identify low-risk patients: 1) endometrioid-type cancer, 2) no evidence of deep myometrial invasion on MRI, 3) no enlarged lymph nodes on MRI, 4) no suspicious metastasis out of the uterine corpus, and 5) serum CA 125 levels less than 35 U/mL...
January 1, 2017: Cancer
https://www.readbyqxmd.com/read/28060140/gynecologic-oncologist-views-influencing-referral-to-outpatient-specialty-palliative-care
#6
Casey M Hay, Carolyn Lefkowits, Megan Crowley-Matoka, Marie A Bakitas, Leslie H Clark, Linda R Duska, Renata R Urban, Lee-May Chen, Stephanie L Creasy, Yael Schenker
OBJECTIVE: Early specialty palliative care is underused for patients with advanced gynecologic malignancies. We sought to understand how gynecologic oncologists' views influence outpatient specialty palliative care referral to help inform strategies for improvement. METHODS/MATERIALS: We conducted a qualitative interview study at 6 National Cancer Institute-designated cancer centers with well-established outpatient palliative care services. Between September 2015 and March 2016, 34 gynecologic oncologists participated in semistructured telephone interviews focused on attitudes, experiences, and preferences related to outpatient specialty palliative care...
January 4, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28040721/vulvar-cancer-version-1-2017-nccn-clinical-practice-guidelines-in-oncology
#7
Wui-Jin Koh, Benjamin E Greer, Nadeem R Abu-Rustum, Susana M Campos, Kathleen R Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Don S Dizon, Oliver Dorigo, Patricia J Eifel, Christine M Fisher, Peter Frederick, David K Gaffney, Ernest Han, Susan Higgins, Warner K Huh, John R Lurain, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W Remmenga, R Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Fidel A Valea, Emily Wyse, Catheryn M Yashar, Nicole McMillian, Jillian Scavone
Vulvar cancer is a rare gynecologic malignancy. Ninety percent of vulvar cancers are predominantly squamous cell carcinomas (SCCs), which can arise through human papilloma virus (HPV)-dependent and HPV-independent pathways. The NCCN Vulvar Cancer panel is an interdisciplinary group of representatives from NCCN Member Institutions consisting of specialists in gynecological oncology, medical oncology, radiation oncology, and pathology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vulvar Cancer provide an evidence- and consensus-based approach for the management of patients with vulvar SCC...
January 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28029447/a-phase-ii-evaluation-of-ixabepilone-in-the-treatment-of-recurrent-persistent-carcinosarcoma-of-the-uterus-an-nrg-oncology-gynecologic-oncology-group-study
#8
Carolyn K McCourt, Wei Deng, Don S Dizon, Heather A Lankes, Michael J Birrer, Michele M Lomme, Matthew A Powell, James E Kendrick, Joel N Saltzman, David Warshal, Meaghan E Tenney, David M Kushner, Carol Aghajanian
BACKGROUND: The primary objectives were to determine the objective response rate (ORR) and safety profile of ixabepilone in women with recurrent or persistent uterine carcinosarcoma (UCS). Secondary objectives included progression-free survival (PFS) and overall survival (OS). Exploratory translational objectives included characterization of class III beta tubulin expression and its association with response, PFS, and OS. METHODS: Patients had measurable disease; up to two prior chemotherapeutic regimens were allowed, but must have included a taxane...
October 28, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/28028994/an-open-label-multicenter-phase-i-trial-of-a-cremophor-free-polymeric-micelle-formulation-of-paclitaxel-combined-with-carboplatin-as-a-first-line-treatment-for-advanced-ovarian-cancer-a-korean-gynecologic-oncology-group-study-kgog-3016
#9
Shin Wha Lee, Yong Man Kim, Young Tae Kim, Soon Beom Kang
OBJECTIVE: This phase I study aimed to determine the maximum tolerated dose (MTD) of Genexol-PM, when combined with carboplatin, as a first-line treatment in patients with advanced ovarian cancer. METHODS: This open-label, multicenter, phase I, dose-escalation study included 18 patients (median age: 59.0 years, range: 40-75 years) diagnosed with advanced epithelial ovarian cancer. All patients had measurable residual disease after debulking surgery. Patients were assigned to groups (n=6 each group) that received different doses of Genexol-PM (220, 260, and 300 mg/m², once every 3 weeks) and 5 area under the curve (AUC) carboplatin...
December 19, 2016: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28024653/comparison-of-2015-medicare-relative-value-units-for-gender-specific-procedures-gynecologic-and-gynecologic-oncologic-versus-urologic-cpt-coding-has-time-healed-gender-worth
#10
M F Benoit, J F Ma, B A Upperman
BACKGROUND: In 1992, Congress implemented a relative value unit (RVU) payment system to set reimbursement for all procedures covered by Medicare. In 1997, data supported that a significant gender bias existed in reimbursement for gynecologic compared to urologic procedures. The present study was performed to compare work and total RVU's for gender specific procedures effective January 2015 and to evaluate if time has healed the gender-based RVU worth. METHODS: Using the 2015 CPT codes, we compared work and total RVU's for 50 pairs of gender specific procedures...
December 23, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/28004030/clinical-trials-in-low-and-middle-income-countries-successes-and-challenges
#11
REVIEW
Surbhi Grover, Melody Xu, Anuja Jhingran, Umesh Mahantshetty, Linus Chuang, William Small, David Gaffney
Gynecologic malignancies affect women in low and middle-income countries (LMICs) at equal or higher rates compared to high income countries (HICs), yet practice guidelines based on clinical trials performed in HICs do not routinely account for resource disparities between these regions. There is a need and growing interest for executing clinical trials in LMICs. This has led to the creation of multinational cooperative groups and the initiation of several ongoing clinical trials in Mexico, China, and Korea...
February 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28002210/european-society-of-gynecological-oncology-statement-on-fibroid-and-uterine-morcellation
#12
Michael J Halaska, Dimitrios Haidopoulos, Frédéric Guyon, Philippe Morice, Ignacio Zapardiel, Vesna Kesic
Recently, there has been an intense discussion about the issue of fibroid and uterine morcellation in relation to the risk of unrecognized uterine sarcoma spread. Morcellation can negatively influence the prognosis of patients, and transecting the specimen into pieces prevents the pathologist from performing proper disease staging. Many societies have published their statements regarding this issue. The European Society for Gynecological Oncology has established a working group of clinicians involved in diagnostics and treatment of oncogynecological patients to provide a statement from the oncological point of view...
January 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28002209/value-of-specialist-pathology-review-in-a-single-statewide-gynecologic-cancer-service
#13
Jerome Melon, Yee Leung, Stuart G Salfinger, Jason Tan, Ganendra Mohan, Paul A Cohen
OBJECTIVE: A case review by specialist diagnostic pathologists as part of a Gynecologic Oncology Multi-disciplinary Tumor group has the potential to influence the management of patients with cancer. The primary aim of this study was to determine the frequency of diagnostic discrepancies between the initial (nonspecialist) and final pathological diagnoses in cases referred to the Gynecologic Oncology Tumor Conference (TC) in Western Australia and the impact of such revised diagnosis on clinical management...
January 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/27991604/a-pilot-randomized-controlled-trial-of-a-wall-climbing-intervention-for-gynecologic-cancer-survivors
#14
Jennifer J Crawford, Jeff K Vallance, Nicholas L Holt, Gordon J Bell, Helen Steed, Kerry S Courneya
PURPOSE/OBJECTIVES: To examine the feasibility and preliminary efficacy of an eight-week supervised climbing intervention for gynecologic cancer survivors (GCSs).
. DESIGN: A pilot randomized, controlled trial.
. SETTING: The Wilson Climbing Center in Edmonton, Alberta, Canada.
. SAMPLE: 35 GCSs who had completed cancer therapy.
. METHODS: GCSs were randomized to an eight-week (16 session) supervised wall climbing intervention (WCI) (n = 24) or usual care (UC) (n = 11)...
January 1, 2017: Oncology Nursing Forum
https://www.readbyqxmd.com/read/27986878/nonsteroidal-anti-inflammatory-drugs-and-endometrial-carcinoma-mortality-and-recurrence
#15
Theodore M Brasky, Ashley S Felix, David E Cohn, D Scott McMeekin, David G Mutch, William T Creasman, Premal H Thaker, Joan L Walker, Richard G Moore, Shashikant B Lele, Saketh R Guntupalli, Levi S Downs, Christa I Nagel, John F Boggess, Michael L Pearl, Olga B Ioffe, Kay J Park, Shamshad Ali, Louise A Brinton
BACKGROUND: Recent data suggest that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with reductions in endometrial cancer risk, yet very few have examined whether their use is related to prognosis among endometrial cancer patients. METHODS: Study subjects comprised 4374 participants of the NRG Oncology/Gynecology Oncology Group 210 Study with endometrial carcinoma who completed a presurgical questionnaire that assessed history of regular prediagnostic NSAID use and endometrial cancer risk factors...
March 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/27930278/for-love-not-money-the-financial-implications-of-surgical-fellowship-training
#16
Paul M Inclan, Adam S Hyde, Michael Hulme, Jeffrey E Carter
Surgical residents cite increased income potential as a motivation for pursuing fellowship training, despite little evidence supporting this perception. Thus, our goal is to quantify the financial impact of surgical fellowship training on financial career value. By using Medical Group Management Association and Association of American Medical Colleges physician income data, and accounting for resident salary, student debt, a progressive tax structure, and forgone wages associated with prolonged training, we generated a net present value (NPV) for both generalist and subspecialist surgeons...
September 2016: American Surgeon
https://www.readbyqxmd.com/read/27926776/synuclein-%C3%AE-in-uterine-serous-carcinoma-impacts-survival-an-nrg-oncology-gynecologic-oncology-group-study
#17
Abigail D Winder, Kruti P Maniar, Jian-Jun Wei, Dachao Liu, Denise M Scholtens, John R Lurain, Julian C Schink, Barbara M Buttin, Virginia L Filiaci, Heather A Lankes, Nilsa C Ramirez, Kay Park, Meenakshi Singh, Richard W Lieberman, Robert S Mannel, Matthew A Powell, Floor J Backes, Cara A Mathews, Michael L Pearl, Angeles Alvarez Secord, David J Peace, David G Mutch, William T Creasman, J Julie Kim
BACKGROUND: Synuclein-γ (SNCG) is highly expressed in advanced solid tumors, including uterine serous carcinoma (USC). The objective of the current study was to determine whether SNCG protein was associated with survival and clinical covariates using the largest existing collection of USCs from the Gynecologic Oncology Group (GOG-8023). METHODS: High-density tissue microarrays (TMAs) of tumor tissues from 313 patients with USC were stained by immunohistochemistry for SNCG, p53, p16, FOLR1, pERK, pAKT, ER, PR, and HER2/neu...
December 7, 2016: Cancer
https://www.readbyqxmd.com/read/27864921/what-is-the-role-of-retroperitoneal-exploration-in-optimally-debulked-stage-iiic-epithelial-ovarian-cancer-an-nrg-oncology-gynecologic-oncology-group-ancillary-data-study
#18
Bunja J Rungruang, Austin Miller, Thomas C Krivak, Neil S Horowitz, Noah Rodriguez, Chad A Hamilton, Floor J Backes, Linda F Carson, Michael Friedlander, David G Mutch, Michael J Goodheart, Krishnansu S Tewari, Robert M Wenham, Michael A Bookman, G Larry Maxwell, Scott D Richard
BACKGROUND: The purpose of this study was to determine the effect of retroperitoneal (RP) exploration on progression-free survival (PFS) and overall survival (OS) in epithelial ovarian cancer (EOC) patients with stage IIIC disease who underwent optimal debulking surgery. METHODS: Data were collected from records of the Gynecologic Oncology Group 182 (GOG-182) study of stage IIIC EOC patients cytoreduced to no gross residual disease (R0) or minimal gross residual (<1 cm) disease (MGRD) at primary surgery...
November 16, 2016: Cancer
https://www.readbyqxmd.com/read/27863705/intake-of-selective-beta-blockers-has-no-impact-on-survival-in-patients-with-epithelial-ovarian-cancer
#19
Florian Heitz, Alexandra Hengsbach, Philipp Harter, Alexander Traut, Beyhan Ataseven, Stephanie Schneider, Sonia Prader, Christian Kurzeder, Mareike Sporkmann, Andreas du Bois
BACKGROUND AND OBJECTIVE: Some authors have claimed a significant impact of β-blocking agents on outcome in epithelial ovarian cancer (EOC). This study investigated the impact of concurrent medication with selective beta blockers (SBB) in patients undergoing primary treatment for EOC. METHODS: The study included all consecutive patients with primary EOC treated in two tertiary gynecological-oncologic units between 1999 and 2014. Medication was retrospectively analyzed by chart review...
January 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/27837120/recommendations-for-high-risk-clinical-target-volume-definition-with-computed-tomography-for-three-dimensional-image-guided-brachytherapy-in-cervical-cancer-patients
#20
Tatsuya Ohno, Masaru Wakatsuki, Takafumi Toita, Yuko Kaneyasu, Ken Yoshida, Shingo Kato, Noriko Li, Sunao Tokumaru, Hitoshi Ikushima, Takashi Uno, Shin-Ei Noda, Tomoko Kazumoto, Yoko Harima
Our purpose was to develop recommendations for contouring the computed tomography (CT)-based high-risk clinical target volume (CTVHR) for 3D image-guided brachytherapy (3D-IGBT) for cervical cancer. A 15-member Japanese Radiation Oncology Study Group (JROSG) committee with expertise in gynecological radiation oncology initiated guideline development for CT-based CTVHR (based on a comprehensive literature review as well as clinical experience) in July 2014. Extensive discussions occurred during four face-to-face meetings and frequent email communication until a consensus was reached...
November 10, 2016: Journal of Radiation Research
keyword
keyword
59468
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"